142 related articles for article (PubMed ID: 31186713)
1. The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents.
Kim G; Kim J; Han SY; Hwang IG; Kim HS; Min H
Oncol Lett; 2019 Jun; 17(6):5023-5029. PubMed ID: 31186713
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents.
van Haaften C; van Eendenburg J; Boot A; Corver WE; Haans L; van Wezel T; Trimbos JB
Int J Gynecol Cancer; 2017 Oct; 27(8):1571-1578. PubMed ID: 28604461
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis.
Cousineau I; Abaji C; Belmaaza A
Cancer Res; 2005 Dec; 65(24):11384-91. PubMed ID: 16357146
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 contributes to cell cycle arrest and chemoresistance in response to the anticancer agent irofulven.
Wiltshire T; Senft J; Wang Y; Konat GW; Wenger SL; Reed E; Wang W
Mol Pharmacol; 2007 Apr; 71(4):1051-60. PubMed ID: 17229870
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer treatment in mutation carriers/BRCAness.
Lorusso D; Perotto S
Minerva Ginecol; 2016 Oct; 68(5):566-78. PubMed ID: 26785283
[TBL] [Abstract][Full Text] [Related]
7. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
8. A mutational signature in gastric cancer suggests therapeutic strategies.
Alexandrov LB; Nik-Zainal S; Siu HC; Leung SY; Stratton MR
Nat Commun; 2015 Oct; 6():8683. PubMed ID: 26511885
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
10. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
11. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
[TBL] [Abstract][Full Text] [Related]
12. Association of DNA Repair and Drug Transporter in Relation to Chemosensitivity in Primary Culture of Thai Gastric Cancer Patients.
Wongsirisin P; Limpakan Yamada S; Yodkeeree S; Punfa W; Limtrakul P
Biol Pharm Bull; 2018; 41(3):360-367. PubMed ID: 29491212
[TBL] [Abstract][Full Text] [Related]
13. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
Isakoff SJ; Mayer EL; He L; Traina TA; Carey LA; Krag KJ; Rugo HS; Liu MC; Stearns V; Come SE; Timms KM; Hartman AR; Borger DR; Finkelstein DM; Garber JE; Ryan PD; Winer EP; Goss PE; Ellisen LW
J Clin Oncol; 2015 Jun; 33(17):1902-9. PubMed ID: 25847936
[TBL] [Abstract][Full Text] [Related]
14. [The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer].
Zhao D; Zhang W; Li XG; Wang XB; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):196-200. PubMed ID: 22780973
[TBL] [Abstract][Full Text] [Related]
15. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
16. BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene.
Snouwaert JN; Gowen LC; Latour AM; Mohn AR; Xiao A; DiBiase L; Koller BH
Oncogene; 1999 Dec; 18(55):7900-7. PubMed ID: 10630642
[TBL] [Abstract][Full Text] [Related]
17. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs.
Atipairin A; Canyuk B; Ratanaphan A
Breast Cancer Res Treat; 2011 Feb; 126(1):203-9. PubMed ID: 20878461
[TBL] [Abstract][Full Text] [Related]
18. Successful personalized chemotherapy for metastatic gastric cancer based on quantitative BRCA1 mRNA expression level: A case report.
Huang Y; Wu P; Liu B; DU J
Oncol Lett; 2016 Jun; 11(6):4183-4186. PubMed ID: 27313763
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 and prostate cancer.
Rosen EM; Fan S; Goldberg ID
Cancer Invest; 2001; 19(4):396-412. PubMed ID: 11405179
[TBL] [Abstract][Full Text] [Related]
20. Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer.
Rhiem K; Wappenschmidt B; Bosse K; Köppler H; Tutt AN; Schmutzler RK
Clin Oncol (R Coll Radiol); 2009 Aug; 21(6):448-50. PubMed ID: 19249193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
